Context Therapeutics (CNTX)
Develops CD3-directed bispecific antibodies for solid tumors.
Something off on this page? Send us feedback.
Builds a portfolio of CD3-directed T-cell-engaging bispecific antibodies for solid tumors. Its programs include CTIM-76, CT-95, and CT-202; progress depends on clinical development, regulatory execution, and further capital.
Develops T-cell-engaging bispecific antibodies for solid tumors. Its pipeline includes CTIM-76, which targets CLDN6 and CD3, CT-95, which targets MSLN and CD3, and CT-202, which targets Nectin-4 and CD3. CT-95 was acquired, while CT-202 is subject to an exclusive worldwide license from BioAtla. The company is headquartered in Philadelphia and operates as a clinical-stage oncology developer.
CTIM-76 entered Phase 1 after Context discontinued its ONA-XR oral hormone-therapy program and redirected resources. The programs are designed around CD3-directed T-cell engagement; progress depends on clinical development, regulatory execution, and enough capital to support program spending.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $43.0M · Total debt $245.0K · Total assets $46.1M · Shareholders' equity $38.2M
- Revenue
- $0
- Operating income
- −$15.0M
- Net income
- −$14.6M
No dividends on record.
| Institutions | 68.61% | 63.04M shares | |
|---|---|---|---|
| 81 holders · as of Jun 30, 2026 | |||
| Insiders | 1.23% | 1.13M shares | |
| 3 holders · as of Jun 10, 2025 | |||
| Other | 30.16% | 27.71M shares | |
| remainder | |||
91.88M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Deep Track Capital, LPInstitution | 8.08% | 7.42M | as of Jun 30, 2026 |
Nextech Invest, Ltd.Institution | 8.08% | 7.42M | as of Jun 30, 2026 |
Soleus Capital Management, L.P.Institution | 7.69% | 7.06M | as of Jun 30, 2026 |
Soleus Capital Master Fund, L.P.Institution | 7.58% | 6.96M | filed May 8, 2026 |
BlackRock, Inc.Institution | 6.71% | 6.17M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Xencor
Direct clinical peer in CLDN6-targeted CD3 T-cell engagement
- BeOne Medicines (ADR)
Direct clinical peer in CLDN6×CD3 bispecific antibodies
- Pfizer
Commercial Nectin-4 ADC franchise in urothelial cancer
- Corbus Pharmaceuticals
Clinical Nectin-4 ADC program in head and neck and cervical cancers
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Context Therapeutics | $0.3818 | −1.88% | $35.8M | — | — | — | — |
| Xencor | $24.20 | −3.83% | $1.87B | — | — | 17.8 | +17.5% |
| BeOne Medicines (ADR) | $363.04 | −1.37% | $39.33B | 5.1 | 46.0 | 6.4 | +29.6% |
| Pfizer | $27.92 | −0.04% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Corbus Pharmaceuticals | $7.78 | −1.27% | $145.9M | — | — | — | — |
| Median | 21.0 | 28.0 | 6.4 | +17.5% |